BioSpace News Archive

Irvine-based Biogennix, a market leader in advanced bone regeneration technology, announced that its DirectCell Advanced Bone Grafting System has already been used in over 500 cases.

The role of compounding pharmacies is to make drugs prescribed by doctors for specific patients with needs that can’t be met by commercially available drugs in the market.

EV Biologics Corp announced that it has signed a Manufacturing Services Agreement with Lonza for development of stem/progenitor cell-derived nanotherapeutics and scalable biomanufacturing process.

Curebase, a company committed to democratizing access to clinical studies, and Flow Neuroscience, creator of Europe’s only medically approved transcranial direct current stimulation (tDCS) device and behavioral therapy app for depression, are launching a clinical trial in which participants will test the effectiveness of Flow’s at-home headset in reducing depressive symptoms.

Novocardia, a value-based cardiovascular disease care platform, has launched an innovative heart failure program that combines individualized health coaching and remote patient monitoring to improve the lives of heart failure patients and decrease the need for hospitalizations.

Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational medical chart review subgroup analysis assessing real-world treatment outcomes among African Americans with advanced symptomatic sarcoidosis who initiated therapy with Acthar Gel (repository corticotropin injection).

Casma Therapeutics, Inc. announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the UBS 2022 Global Healthcare Conference on Tuesday, May 24, 2022 at 11:30 a.m. ET in New York, NY.

Apotex Inc., Canada’s leading pharmaceutical manufacturer of generic medicines, announced the Canadian launch of APO-Teriflunomide™ tablets, a generic version of Aubagio®, for the treatment of relapsing remitting multiple sclerosis.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System.

Dr. Dhandayudham brings a wealth of clinical and leadership experience to Awakn. Dr. Dhandayudham has been a Consultant in Addictions Psychiatry since 2005, having trained in Oxford and Cambridge.